Small-Molecule Stabilization of the 14-3-3/Gab2 Protein-Protein Interaction (PPI) Interface-Reference-Cited by-同舟云学术

Small-Molecule Stabilization of the 14-3-3/Gab2 Protein-Protein Interaction (PPI) Interface

Published:2015-12-08 Issue:8 Volume:11 Page:911-918
ISSN:1860-7179
Container-title:ChemMedChem
language:en
Short-container-title:ChemMedChem

Author:

Bier David¹,Bartel Maria²,Sies Katharina³,Halbach Sebastian³⁴⁵,Higuchi Yusuke⁶,Haranosono Yu⁶,Brummer Tilman³⁷,Kato Nobuo⁶,Ottmann Christian¹²

Affiliation:

1. Department of Chemistry; University of Duisburg-Essen; Universitätstr. 7 45141 Essen Germany

2. Department of Biomedical Engineering; Institute for Complex Molecular, Systems; Eindhoven University of Technology; P.O. Box 513 5600 MB Eindhoven The Netherlands

3. Institute of Molecular Medicine & Cell Research (IMMZ); Faculty of Medicine; University of Freiburg; Stefan-Meier-Str. 17 79104 Freiburg Germany

4. Faculty of Biology; University of Freiburg; Schänzlestr. 1 79104 Freiburg Germany

5. Spemann Graduate School of Biology & Medicine; University of Freiburg; Albertstr. 19A 79104 Freiburg Germany

6. The Institute of Scientific & Industrial Research; Osaka University; Osaka 567-0047 Japan

7. BIOSS: Centre for Biological Signaling Studies; University of Freiburg; Schänzlestr. 18 79104 Freiburg Germany

Funder

European Commission′s Horizon 2020 Marie Skłodowska-Curie action (MSCA)

Collaborative Research Center SFB1093

Deutsche Forschungsgemeinschaft (DFG)

Deutsche Krebshilfe

Mildred-Scheel Program

DFG Excellence Initiative

DFG Heisenberg program

Publisher

Wiley

Subject

Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics,Molecular Medicine,Drug Discovery,Biochemistry,Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cmdc.201500484/fullpdf

Reference46 articles.

1. Structure-based prediction of protein–protein interactions on a genome-wide scale

2. Estimating the size of the human interactome

3. Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

4. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia

5. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fragment-Based Interrogation of the 14–3–3/TAZ Protein–Protein Interaction;Biochemistry;2024-08-22

2. 14‐3‐3 Protein‐Protein Interactions: From Mechanistic Understanding to Their Small‐Molecule Stabilization;ChemBioChem;2024-06-24

3. Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite;Cancer Cell;2024-06

4. Usnic Acid Targets 14-3-3 Proteins and Suppresses Cancer Progression by Blocking Substrate Interaction;JACS Au;2024-04-11

5. Small molecules targeting protein–protein interactions for cancer therapy;Acta Pharmaceutica Sinica B;2023-10